← Back to Search

Horyzons Platform for Psychosis

N/A
Waitlist Available
Led By Diana Perkins, MD, MPH
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial is testing whether an online social media platform with therapeutic content, called Horyzons, can help people with first-episode psychosis. The trial will enroll clients from 4 FEP clinics in North Carolina, who will be assigned to one of two groups. Cohort 1 will have access to the platform for 3 months and cohort 2 will have access to the platform for 6 months. All interventions and assessments will be completed online/remotely due to the global pandemic.

Who is the study for?
This trial is for individuals aged 18-35 with conditions like schizophrenia or related disorders, who are not hospitalized for psychiatric reasons recently, haven't changed their psychiatric meds in the last month, and have no recent self-harm thoughts. They must be able to access the internet and be receiving services at one of four FEP clinics in North Carolina.Check my eligibility
What is being tested?
The trial tests 'Horyzons', an online social media platform offering therapeutic content as part of treatment for first-episode psychosis. Participants will use it remotely due to COVID-19 restrictions—some for 3 months (Cohort 1) and others for 6 months (Cohort 2).See study design
What are the potential side effects?
Since Horyzons is a digital intervention rather than a medication, traditional side effects aren't expected. However, users may experience discomfort or stress from using the platform or engaging with its content.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Change in Medical Outcomes Study (MOS) Social Support Survey - Total Score (Both Cohorts)
Mean Change in UCLA Loneliness Scale Score (Both Cohorts)
Secondary outcome measures
Mean Change in Psychological Wellbeing Scale Short Form - Total Score (Both Cohorts)
Anxiety
Other outcome measures
Mean Change in Medical Outcomes Study (MOS) Social Support Survey - Affectionate Support Subscale Score (Both Cohorts)
Mean Change in Medical Outcomes Study (MOS) Social Support Survey - Emotional/Informational Support Subscale Score (Both Cohorts)
Mean Change in Medical Outcomes Study (MOS) Social Support Survey - Positive Social Interaction Subscale Score (Both Cohorts)
+21 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: FEP CliniciansExperimental Treatment1 Intervention
Approximately 40 providers (clinicians and peer support specialists) affiliated with First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in a focus group discussing the implementation and integration of Horyzons into their care routine with clients who participated in the study.
Group II: FEP ClientsExperimental Treatment1 Intervention
Approximately 90 first episode psychosis (FEP) clients recruited from First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in the online platform Horyzons for 3 months (cohort 1) or 6 months (cohort 2) as a part of their care plan. Participants will be encouraged to use both the therapeutic content and the moderated online community throughout their time in the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Horyzons USA
2021
N/A
~90

Find a Location

Who is running the clinical trial?

North Carolina Department of Health and Human ServicesOTHER_GOV
13 Previous Clinical Trials
131,876 Total Patients Enrolled
1 Trials studying Schizophrenia
70 Patients Enrolled for Schizophrenia
University of North Carolina, Chapel HillLead Sponsor
1,508 Previous Clinical Trials
4,190,736 Total Patients Enrolled
26 Trials studying Schizophrenia
2,570 Patients Enrolled for Schizophrenia
Diana Perkins, MD, MPHPrincipal InvestigatorUniversity of North Carolina, Chapel Hill - School of Medicine
3 Previous Clinical Trials
132 Total Patients Enrolled
1 Trials studying Schizophrenia
70 Patients Enrolled for Schizophrenia

Media Library

Horyzons USA Clinical Trial Eligibility Overview. Trial Name: NCT04673851 — N/A
Schizophrenia Research Study Groups: FEP Clients, FEP Clinicians
Schizophrenia Clinical Trial 2023: Horyzons USA Highlights & Side Effects. Trial Name: NCT04673851 — N/A
Horyzons USA 2023 Treatment Timeline for Medical Study. Trial Name: NCT04673851 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the purpose of this clinical investigation?

"The primary aim of this 6-month trial is to assess the mean change in MOS Social Support Survey Total Score across both cohorts. Secondary objectives include determining the changes in Psychological Wellbeing Scale Short Form and SIAS scores for each cohort over time."

Answered by AI

Are there any vacancies for this trial that participants may apply to join?

"This medical research, first published on January 19th 2021, is actively seeking participants. The trial's information was most recently revised on February 10th 2022 according to clinicaltrials.gov."

Answered by AI

What criteria must be met for individuals to take part in this clinical experiment?

"This medical trial is targeting 117 people with schizophreniform disorders within the age range of 18-35. To be qualified, individuals must meet both criteria."

Answered by AI

How many participants are being monitored in this research project?

"Confirmed. According to the information on clinicaltrials.gov, this trial is in need of patient participation and has been open since January 19th 2021. The study requires 117 individuals from a single location and was last updated February 10th 2022."

Answered by AI

Is this trial open to individuals aged 35 or above?

"Individuals aged 18 to 35 are the only ones eligible for this medical trial. Those younger than 18 and older than 65 can explore 352 and 903 alternative trials respectively."

Answered by AI
~21 spots leftby May 2025